U.S. Markets closed

Wright Medical Augment potential not priced in, says Brean Capital

Brean Capital continues to recommend Wright Medical following its recent investor field trip. The firm sees potential upside to estimates and thinks the current share price does not have the potential for Augment priced into the stock. Brean keeps its Buy rating and $40 price target on the shares.